Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The base Gland business posted ?11,790 million in revenue, up 16% YoY
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Subscribe To Our Newsletter & Stay Updated